Boston Medical Technologies Expands Sales Force, Hires Eleven Medical Industry Veterans.

Business/Technology Editors and Health/Medical Writers

WAKEFIELD, Mass.--(BW HealthWire)--Sept. 28, 2000

Team to Drive Sales and Adoption of Critical Heart Rate Variability 

Test in Northeast, Central, Southeast, Mid-Atlantic and

Western Regions

Boston Medical Technologies, the pioneer of office and hospital-based, non-invasive systems for measurement of heart rate variability (HRV), today announced that it has hired eleven new sales representatives who will be responsible for territories in the Northeast, Central, Southeast, Mid-Atlantic and Western portions of the United States. The expanded sales force will be responsible for generating sales of the Anscore(TM) Health Management System, the Company's heart rate variability test, in their assigned regions as well as to educate and train healthcare professionals and develop close ties with the physician community. The Anscore Health Management System is already integrated at many leading healthcare facilities including Mid-America Diabetes Associates in Wichita, Kansas, where more than 93,000 patients are provided medical care.

"The expansion of our sales force represents the next phase of Boston Medical Technologies' growth as demand for the Anscore Health Management System from leading medical facilities across the country grows," said Jack Kromar, Vice President of Sales. "Heart rate variability testing has gained momentum from medical associations, such as the American Heart Association (AHA) and the American Association of Clinical Endocrinologists (AACE), that now recommend HRV testing as the standard of care for patients with diabetes. Boston Medical Technologies is now able to better meet requests from physicians nationwide and to offer more personalized and comprehensive services."

The Anscore Health Management System is an easy to perform heart rate variability testing system. Extensive published clinical data reports that heart rate variability can be used as an indicator of autonomic nervous system dysfunction--damage to the autonomic nervous system--which is prevalent in patients with chronic diseases such as diabetes. (1)(2)(3)(4) Additionally, AHA and AACE recently declared that heart rate variability is the recommended test for detecting autonomic dysfunction in diabetes.(5)

From taking the test to receiving the results, heart rate variability testing with the Anscore Health Management System only takes 15 minutes, enabling the physician and patient to immediately discuss its implications for treatment and compliance. Upon completion of the test, a telemetry device immediately transmits the test data to a centralized Process Center where the results are reviewed by technicians and compared with previous tests to determine any trends. The results are transmitted back to the physician and printed out in a comprehensive report for interpretation and review.

Boston Medical Technologies' office-based heart rate variability test is the first testing system that provides treating physicians with a thorough view of a patient's autonomic nervous system. Standard medical instruments are prone to omission of critical information, preventing detection and subsequent monitoring of the complications of conditions such as diabetes. Early intervention may prevent, slow or completely stop the onset or progression of clinical symptoms. The mortality rate associated with autonomic neuropathy is significant. According to published research, loss of heart rate variability in diabetic autonomic neuropathy is associated with up to a 50 percent mortality rate within five years of the onset of clinical symptoms.(6) Furthermore, loss of heart rate variability predicts poor outcome for strokes, heart attacks and renal function.(1) By year's end, Boston Medical Technologies expects to have a thirty-six member medical products sales force to further enable access to the Anscore Health Management System, a necessary testing tool providing critical results for the health and well being of diabetic patients.

About Boston Medical Technologies

An emerging e-health company, Boston Medical Technologies is pioneering the development and worldwide deployment of office and hospital-based, non-invasive heart rate variability testing systems to improve the quality and cost-effectiveness of clinical care. Founded in 1994, Boston Medical Technologies is headquartered in Wakefield, Mass. For more information, contact Boston Medical Technologies at [phone] or on the Web at http://www.bosmedtech.com.

Under development since 1994, the Anscore Health Management System received 510(k) clearance from the Food and Drug Administration (FDA) for heart rate variability testing on June 11, 1999. Boston Medical Technologies has also been granted ISO 9001/ EN 46001 certification for their full quality assurance system under the Medical Device Directive.

(1) Vinik, Al, MD, PhD, and Suwanwalaikorn, S, MD: Autonomic Neuropathy, In deFronzo, R.M. (ed). Current Therapy of Diabetes Mellitus. Yearbook Inc. 1997; 165-176.

(2) Robertson, D; Beck, C; Gary, T; Picklo, M: Classification of Autonomic Disorders. Int Angiol. 12 (2): 1993; 93-1002.

(3) Low, PA. Autonomic Neuropathy. Semin Neurol 1987 Mar; 7 (1): 49-57.

(4) Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart Rate Variability: Standards of Measurement, Physiological Interpretation and Clinical Use. Circulation: Vol. 93, No. 5, 1996.

(5) The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-management - 2000 Update, Endocrine Practice 2000; 6(1): 43-84; American Heart Association, 1999. AHA Scientific Statement: Diabetes and cardiovascular disease. Circulation 100:1134-1146.

(6) Ewing, DJ; Campbell, IW; Clarke, BF: The Natural History of Diabetic Neuropathy. Quarterly Journal of Medicine 1980; 49 (193): 95-108).